**Supplementary File 2.**

**About the REALISE Working Group**

1. The working group is named **REAL**-World Data **I**n A**S**ia for H**E**alth Technology Assessment in Reimbursement **(REALISE)**. The acronym REALISE signifies our desire to realize (i.e. to cause to happen or to facilitate) the potential of real-world data (RWD)/ real-world evidence (RWE) while realizing (i.e. being aware of) its strengths and limitations.
2. The REALISE working group comprises three subgroups: (1) International Advisory Panel (IAP), (2) HTAsiaLink working group, and (3) Core Team. The IAP are the chair/ head/ scientist in the leading HTA organizations in Australia, Canada, the UK and the US, where the use of RWD/RWE in HTA is more mature. They share with other team members how RWD/ RWE are collected, analyzed and assessed in their health systems. The HTAsiaLink working group include representatives from 11 Asian health systems (Bhutan, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan and Thailand), who share their experiences and perspectives on opportunities and challenges in using RWD/ RWE in their local contexts. The core team is made up of staff from Saw Swee Hock School of Public Health (SSHSPH), National University of Singapore (NUS), and Health Intervention and Technology Assessment Program (HITAP), Ministry of Health, Thailand. Additionally, the REALISE working group received an unrestricted grant from the International Decision Support Initiative (iDSI). iDSI sent an observer to the first face-to-face meeting, but had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Supplementary Figure 1 provides the organization chart of the working group.
3. The mission of the working group is to advance the science of using RWD from non-clinical trials for HTA to inform reimbursement decision-making in Asia. Our vision is that high quality, relevant and reliable RWD from non-clinical trials conducted in Asia will be used in HTA to inform reimbursement decision-making across the region. Supplementary Figure 2 lists the objectives of the guidance to be developed by the working group.